FDA Seeks Alternatives To QT Interval For Assessing Risk Of Torsade de Pointes
Executive Summary
A clinical study funded by the Critical Path Initiative is looking at the change in a number of electrocardiogram parameters in patients given drugs known to prolong the QT interval and with varying risks for the abnormal heart rhythm.
You may also be interested in...
FDA Seeks Specificity Over Sensitivity To ID Potentially Proarrhythmic Drugs
The agency is looking at preclinical measurement of a drug’s effect on multiple ion channels, in silico modeling and stem cell assays as a possible alternative to “thorough” QT tests to assess the therapy’s impact on heart rhythm.
QT Guidance Reducing Number Of Drugs Leaving Early Development, Firms Say
Stricter guidelines on QT prolongation are forcing manufacturers to drop compounds earlier in the development process, participants said during an FDA/Duke Cardiac Safety and Critical Path Initiative Think Tank meeting Oct. 11
QT Prolongation Trial For All Drugs Recommended By ICH Draft Guidance
All drugs should undergo a single cardiac QT interval prolongation trial early in development, an International Conference on Harmonization draft guidance on clinical evaluation of QT prolongation, released Sept. 13, states